Survey Shows More NSCLC Patients Getting EGFR Testing, but Results Often Don't Inform Care | GenomeWeb

NEW YORK (GenomeWeb) – Although more newly diagnosed non-small cell lung cancer patients are receiving EGFR mutation testing as recommended by guidelines, a significant proportion of oncologists aren't basing patients' treatment decisions on test results, a global survey conducted by drugmaker Boehringer Ingelheim has shown.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.